<DOC>
	<DOCNO>NCT02129582</DOCNO>
	<brief_summary>This phase I trial study side effect best dose targeted marrow irradiation give fludarabine phosphate busulfan donor progenitor cell transplant treat patient hematologic malignancy . Targeted marrow irradiation type specialize radiation therapy delivers high dose radiation directly cancer cell , may kill cancer cell cause less damage normal cell . Giving targeted marrow irradiation chemotherapy drug , fludarabine phosphate busulfan , donor progenitor cell transplant may help stop growth cancer cell . It may also stop patient 's immune system reject donor 's progenitor cell . When healthy progenitor cell donor infused patient may help patient 's bone marrow make progenitor cell , red blood cell , white blood cell , platelet .</brief_summary>
	<brief_title>Targeted Marrow Irradiation , Fludarabine Phosphate , Busulfan Before Donor Progenitor Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose targeted marrow irradiation give combination fludarabine ( fludarabine phosphate ) busulfan condition regimen allogeneic hematopoietic progenitor cell transplantation . SECONDARY OBJECTIVES : I . To describe toxicity profile condition regimen target marrow irradiation ( TMI ) , fludarabine busulfan allogeneic hematopoietic progenitor transplantation . II . To describe use two technique deliver TMI , volumetric modulate arc therapy ( VMAT ) TomoTherapy , patient 's compute tomography ( CT ) simulation image describe difference organ avoidance target coverage , planning time , treatment delivery time . III . To determine disease response status 100 day allogeneic hematopoietic progenitor cell transplantation condition regimen TMI , fludarabine busulfan . IV . To determine rate acute graft versus host disease allogeneic hematopoietic progenitor cell transplantation condition regimen TMI , fludarabine busulfan . OUTLINE : This dose-escalation study TMI . CONDITIONING : Patients undergo TMI twice daily ( BID ) day -10 -7 . Patients also receive fludarabine phosphate intravenously ( IV ) 1 hour day -6 -2 busulfan IV orally ( PO ) day -5 -4 . TRANSPLANT : Patients undergo allogeneic hematopoietic progenitor cell transplant day 0 . GRAFT-VERSUS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients receive anti-thymocyte globulin IV day -3 -2 , tacrolimus IV PO begin day -1 least 6 month taper begin 4 month , methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow 100 day , 6 month , 12 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients ineligible receive full myeloablative condition regimen allogeneic hematopoietic progenitor cell transplant due age comorbidities Patients must histologically cytologically diagnosis hematologic malignancy indication allogeneic hematopoietic progenitor cell transplantation , ineligible receive full ablative condition regimen part transplantation , include : Acute myeloid leukemia Acute lymphocytic leukemia Non Hodgkin lymphoma Hodgkin lymphoma Multiple myeloma Myelodysplastic syndrome Chronic lymphocytic leukemia Chronic myeloid leukemia : Myeloproliferative syndrome include myelofibrosis Complete remission necessary enrollment protocol Require allogeneic hematopoietic progenitor cell transplantation ( HPCT ) either match sibling , mismatch ( 1 allele ) sibling , match unrelated donor ( MUD ) mismatch ( 1 allele ) unrelated donor Previous hematopoietic progenitor cell transplantation allow ; minimum 6 month elapse prior autologous hematopoietic progenitor cell transplantation minimum 6 month elapse since prior allogeneic hematopoietic progenitor cell transplantation ; prior transplantation conditioning regimen use total body irradiation allow Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 12 week , opinion document investigator Patients must adequate hepatic , renal function define : exclusion presence cytopenia Total bilirubin ≤ 1.5 time institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) ≤ 2.5 X institutional upper limit normal Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) ≤ 2.5 X institutional upper limit normal Creatinine clearance ( calculate CockroftGault formula ) ≥ 60 ml/min Pulmonary Function Tests ( FEV1 , FVC , DLCO ) 40 % . Women childbearing potential men must agree use adequate contraception ( double barrier method birth control abstinence ) time study entry , duration study participation 3 month complete treatment ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately Subjects must ability understand willingness sign write informed consent document Prior nonhematologic treatment toxicity must resolve ≤ grade 1 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 , exception follow grade 2 toxicity : alopecia ; dry skin ; spleen disorder , hear impairment ; tinnitus ; hypothyroidism ; hyperthyroidism ; endocrine disorder ; blur vision ; cataract ; constipation ; gastroesophageal reflux ; fatigue ; abnormal coagulation test INR and/or aPTT ; weight gain weight loss ; anorexia ; glucose intolerance ; hypoalbuminemia ; hypokalemia ; muscle weakness ; dysgeusia ; paresthesia ; peripheral motor and/or sensory neuropathy ; hot flash ; hypertension . Patients must receive investigational agent within 14 day initiation condition regimen Patients untreated brain metastasis exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition fludarabine busulfan agent use study Prior allogeneic hematopoietic progenitor cell transplantation Prior autologous hematopoietic progenitor cell transplantation condition regimen include total body irradiation Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; exclusion criterion include underlying disease patient undergo hematopoietic progenitor cell transplantation Pregnant breastfeed woman exclude study ; breastfeed discontinue Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible Patients history therapy radiation therapy exclude Due technical limitation TMI , patient must taller 1.9 ( 6 foot 4 inch ) , wide elbow elbow supine position 60 cm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>